Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Oncogene ; 36(23): 3346-3356, 2017 06 08.
Article in English | MEDLINE | ID: mdl-28114278

ABSTRACT

In 11q23 leukemias, the N-terminal part of the mixed lineage leukemia (MLL) gene is fused to >60 different partner genes. In order to define a core set of MLL rearranged targets, we investigated the genome-wide binding of the MLL-AF9 and MLL-AF4 fusion proteins and associated epigenetic signatures in acute myeloid leukemia (AML) cell lines THP-1 and MV4-11. We uncovered both common as well as specific MLL-AF9 and MLL-AF4 target genes, which were all marked by H3K79me2, H3K27ac and H3K4me3. Apart from promoter binding, we also identified MLL-AF9 and MLL-AF4 binding at specific subsets of non-overlapping active distal regulatory elements. Despite this differential enhancer binding, MLL-AF9 and MLL-AF4 still direct a common gene program, which represents part of the RUNX1 gene program and constitutes of CD34+ and monocyte-specific genes. Comparing these data sets identified several zinc finger transcription factors (TFs) as potential MLL-AF9 co-regulators. Together, these results suggest that MLL fusions collaborate with specific subsets of TFs to deregulate the RUNX1 gene program in 11q23 AMLs.


Subject(s)
Chromosomes, Human, Pair 11/genetics , Core Binding Factor Alpha 2 Subunit/metabolism , Enhancer Elements, Genetic , Gene Expression Regulation, Neoplastic , Leukemia, Myeloid, Acute/genetics , Myeloid-Lymphoid Leukemia Protein/metabolism , Oncogene Proteins, Fusion/metabolism , Adult , Core Binding Factor Alpha 2 Subunit/genetics , Female , High-Throughput Nucleotide Sequencing/methods , Humans , Infant , Leukemia, Myeloid, Acute/metabolism , Leukemia, Myeloid, Acute/pathology , Male , Middle Aged , Myeloid-Lymphoid Leukemia Protein/genetics , Neoplasm Staging , Oncogene Proteins, Fusion/genetics , Prognosis , Promoter Regions, Genetic
2.
Oncogene ; 35(15): 1965-76, 2016 Apr 14.
Article in English | MEDLINE | ID: mdl-26148230

ABSTRACT

The ETS transcription factor ERG has been implicated as a major regulator of both normal and aberrant hematopoiesis. In acute myeloid leukemias harboring t(16;21), ERG function is deregulated due to a fusion with FUS/TLS resulting in the expression of a FUS-ERG oncofusion protein. How this oncofusion protein deregulates the normal ERG transcription program is unclear. Here, we show that FUS-ERG acts in the context of a heptad of proteins (ERG, FLI1, GATA2, LYL1, LMO2, RUNX1 and TAL1) central to proper expression of genes involved in maintaining a stem cell hematopoietic phenotype. Moreover, in t(16;21) FUS-ERG co-occupies genomic regions bound by the nuclear receptor heterodimer RXR:RARA inhibiting target gene expression and interfering with hematopoietic differentiation. All-trans retinoic acid treatment of t(16;21) cells as well as FUS-ERG knockdown alleviate the myeloid-differentiation block. Together, the results suggest that FUS-ERG acts as a transcriptional repressor of the retinoic acid signaling pathway.


Subject(s)
Chromosomes, Human, Pair 16/genetics , Chromosomes, Human, Pair 21/genetics , Gene Expression Regulation, Neoplastic/genetics , Hematopoiesis/physiology , Leukemia, Myeloid, Acute/genetics , Leukemia, Myelomonocytic, Acute/genetics , Neoplasm Proteins/physiology , Oncogene Proteins, Fusion/physiology , RNA-Binding Protein FUS/physiology , Signal Transduction/physiology , Translocation, Genetic , Tretinoin/physiology , Amino Acid Motifs , Cell Line, Tumor , Chromosomes, Human, Pair 16/ultrastructure , Chromosomes, Human, Pair 21/ultrastructure , Dimerization , Enhancer Elements, Genetic , Hematopoietic Stem Cells/pathology , Humans , Leukemia, Myeloid, Acute/pathology , Leukemia, Myeloid, Acute/physiopathology , Leukemia, Myelomonocytic, Acute/pathology , Leukemia, Myelomonocytic, Acute/physiopathology , Multiprotein Complexes , Neoplasm Proteins/genetics , Neoplastic Stem Cells/pathology , Oncogene Proteins, Fusion/antagonists & inhibitors , Oncogene Proteins, Fusion/genetics , Promoter Regions, Genetic , Protein Binding , Protein Interaction Mapping , Proto-Oncogene Proteins/metabolism , RNA Interference , RNA, Small Interfering/genetics , RNA-Binding Protein FUS/antagonists & inhibitors , RNA-Binding Protein FUS/genetics , Receptors, Retinoic Acid/metabolism , Retinoic Acid Receptor alpha , Retinoid X Receptors/metabolism , Signal Transduction/drug effects , Trans-Activators/metabolism , Transcription Factors/metabolism , Tretinoin/pharmacology , U937 Cells
3.
J Steroid Biochem Mol Biol ; 122(4): 204-11, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20599613

ABSTRACT

Several estrogenic compounds including the isoflavonoid genistein have been reported to induce a higher maximal response than the natural estrogen 17ß-estradiol in in vitro luciferase based reporter gene bioassays for testing estrogenicity. The phenomenon has been referred to as superinduction. The mechanism underlying this effect and thus also its biological relevance remain to be elucidated. In the present study several hypotheses for the possible mechanisms underlying this superinduction were investigated using genistein as the model compound. These hypotheses included (i) a non-estrogen receptor (ER)-mediated mechanism, (ii) a role for an ER activating genistein metabolite with higher ER inducing activity than genistein itself, and (iii) a post-transcriptional mechanism that is not biologically relevant but specific for the luciferase based reporter gene assays. The data presented in this study indicate that induction and also superinduction of the reporter gene is ER-mediated, and that superinduction by genistein could be ascribed to stabilization of the firefly luciferase reporter enzyme increasing the bioluminescent signal during the cell-based assay. This indicates that the phenomenon of superinduction may not be biologically relevant but may rather represent a post-transcriptional effect on enzyme stability.


Subject(s)
Gene Expression Regulation , Genes, Reporter , Genistein/metabolism , Luciferases/genetics , Phytoestrogens/metabolism , Receptors, Estrogen/metabolism , Cell Line, Tumor , Cell Proliferation , Estradiol/metabolism , Humans
4.
J Steroid Biochem Mol Biol ; 112(4-5): 171-8, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18955141

ABSTRACT

This study investigates the importance of the intracellular ratio of the two estrogen receptors ERalpha and ERbeta for the ultimate potential of the phytoestrogens genistein and quercetin to stimulate or inhibit cancer cell proliferation. This is of importance because (i) ERbeta has been postulated to play a role in modulating ERalpha-mediated cell proliferation, (ii) genistein and quercetin may be agonists for both receptor types and (iii) the ratio of ERalpha to ERbeta is known to vary between tissues. Using human osteosarcoma (U2OS) ERalpha or ERbeta reporter cells it was shown that compared to estradiol (E2), genistein and quercetin have not only a relatively greater preference for ERbeta but also a higher maximal potential for activating ERbeta-mediated gene expression. Using the human T47D breast cancer cell line with tetracycline-dependent ERbeta expression (T47D-ERbeta), the effect of a varying intracellular ERalpha/ERbeta ratio on E2- or pythoestrogen-induced cell proliferation was characterised. E2-induced proliferation of cells in which ERbeta expression was inhibited was similar to that of the T47D wild type cells, whereas this E2-induced cell proliferation was no longer observed when ERbeta expression was increased. With increased expression of ERbeta the phytoestrogen-induced cell proliferation was also reduced. These results point at the importance of the cellular ERalpha/ERbeta ratio for the ultimate effect of (phyto)estrogens on cell proliferation.


Subject(s)
Cell Proliferation/drug effects , Estrogen Receptor alpha/physiology , Estrogen Receptor beta/physiology , Genistein/pharmacology , Phytoestrogens/pharmacology , Quercetin/pharmacology , Breast Neoplasms/pathology , Cell Line, Tumor , Estradiol/pharmacology , Estrogen Receptor beta/antagonists & inhibitors , Humans , Tetracycline/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...